DrugPatentWatch Database Preview
RITALIN LA Drug Profile
Which patents cover Ritalin La, and what generic alternatives are available?
Ritalin La is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has one hundred and forty-two patent family members in thirty-three countries.
The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for RITALIN LA
| International Patents: | 142 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 106 |
| Patent Applications: | 4,234 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RITALIN LA |
| Drug Sales Revenues: | Drug sales revenues for RITALIN LA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITALIN LA |
| DailyMed Link: | RITALIN LA at DailyMed |
See drug prices for RITALIN LA
Recent Clinical Trials for RITALIN LA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Taiwan University Hospital | N/A |
| Second Affiliated Hospital of Nanchang University | Phase 4 |
| Matthew O'Brien | Phase 4 |
Recent Litigation for RITALIN LA
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Recro Gainesville LLC v. Actavis Laboratories FL, Inc. | 2017-10-30 |
| Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 2015-09-15 |
| Recro Gainesville LLC v. Alvogen Malta Operations Ltd. | 2014-11-03 |
Pharmacology for RITALIN LA
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Synonyms for RITALIN LA
| .alpha.-Phenyl-2-piperidineacetic acid methyl ester |
| 113-45-1 |
| 113-45-1 (Parent) |
| 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester |
| 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R*,R*)-(+-)- |
| 298-59-9 |
| 298-59-9 (hydrochloride) |
| 298M599 |
| 4311/B Ciba |
| AB01563134_01 |
| AC1L1HJM |
| AC1L1SQ4 |
| AC1Q5YRN |
| AKOS016010356 |
| AKOS022506757 |
| alpha-Phenyl-2-piperidineacetic acid methyl ester |
| alpha-phenyl-2-piperidineacetic acid methyl ester hydrochloride |
| alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester |
| AN-23356 |
| API0003340 |
| API0008866 |
| BCP18286 |
| BDBM50062912 |
| BRD-A19585813-003-01-7 |
| C 4311 |
| C07196 |
| Calocain |
| CAS-298-59-9 |
| CC-30903 |
| CCG-213572 |
| CCRIS 6258 |
| Centedein |
| Centedein (Salt/Mix) |
| Centedrin |
| Centedrin (Salt/Mix) |
| Centedrine |
| Centedrine (Salt/Mix) |
| Centredin |
| CHEBI:31836 |
| CHEBI:84276 |
| CHEMBL1722 |
| CHEMBL796 |
| ciba 4311b |
| Concerta |
| Concerta (TN) |
| Concerta, Methylin, Ritalin |
| Cotempla XR-ODT |
| CS-4657 |
| CS-4658 |
| d-methylphenidate HCl |
| D01296 |
| D04999 |
| Daytrana |
| Daytrana (TN) |
| DB00422 |
| DEA No. 1724 |
| DSSTox_CID_886 |
| DSSTox_GSID_20886 |
| DSSTox_RID_75843 |
| DTXSID5023299 |
| DTXSID8020886 |
| DUGOZIWVEXMGBE-UHFFFAOYSA-N |
| EINECS 204-028-6 |
| EINECS 206-065-3 |
| FT-0603372 |
| FT-0672046 |
| FT-0672047 |
| FT-0700534 |
| GTPL7236 |
| H-Tic-OtBu.HCl |
| HSDB 3126 |
| HY-B1091 |
| HY-B1091A |
| Jornay PM (a.k.a. HLD200) |
| JUMYIBMBTDDLNG-UHFFFAOYSA-N |
| L001307 |
| LS-42 |
| LS-565 |
| Medikinet |
| Meridil |
| Meridil hydrochloride |
| Metadate |
| Metadate (TN) |
| Metadate CD |
| Metadate ER |
| Methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate |
| Methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate |
| Methyl .alpha.-phenyl-2-piperidine-acetate |
| Methyl .alpha.-phenyl-2-piperidineacetate |
| Methyl .alpha.-phenyl-2-piperidineacetate hydrochloride |
| Methyl (2-phenyl-2-(2-piperidyl)acetate) |
| methyl 2-phenyl-2-(2-piperidyl)acetate hydrochloride |
| Methyl 2-phenyl-2-(piperidin-2-yl)acetate |
| Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride |
| methyl 2-phenyl-2-piperidin-2-ylacetate |
| methyl 2-phenyl-2-piperidin-2-ylacetate hydrochloride |
| methyl alpha-phenyl-2-piperidine-acetate hydrochloride |
| Methyl alpha-phenyl-2-piperidineacetate hydrochloride |
| Methyl alpha-phenyl-alpha-(2-piperidyl)acetate |
| Methyl alpha-phenyl-alpha-2-piperidinylacetate |
| methyl alpha-piperid-2-ylphenylacetate |
| Methyl phenidate |
| Methyl phenidyl acetate |
| Methyl phenidylacetate |
| Methyl Phenidylacetate Hydrochloride |
| Methyl phenyl(2-piperidinyl)acetate # |
| methyl phenyl(piperidin-2-yl)acetate |
| methyl phenyl(piperidin-2-yl)acetate hydrochloride |
| Methylfenidan |
| Methylin |
| Methylin (Salt/Mix) |
| Methylin ER |
| Methylofenidan |
| Methylphen |
| Methylphenidan |
| Methylphenidan Hydrochloride |
| methylphenidate |
| Methylphenidate (hydrochloride) |
| METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R) |
| Methylphenidate (USAN/INN) |
| Methylphenidate [INN:BAN] |
| Methylphenidate [USAN:INN:BAN] |
| Methylphenidate HCl |
| METHYLPHENIDATE HYDROCHLORIDE |
| Methylphenidate hydrochloride (JAN/USP) |
| Methylphenidate hydrochloride [USAN:JAN] |
| Methylphenidate hydrochloride [USP:JAN] |
| Methylphenidate Hydrochloride ER |
| Methylphenidate hydrochloride solution, (Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material |
| Methylphenidate hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Methylphenidate Hydrochloride(Ritalin hydrochloride) |
| METHYLPHENIDATE HYDROCHLORIDE(SEE ALSO: METHYLPHENIDATE, CAS 113-45-1, NTPNO M20344) |
| Methylphenidate.HCl |
| Methylphenidate(Ritalin) |
| Methylphenidatum |
| Methylphenidatum [INN-Latin] |
| Methylphenidylacetate hydrochloride |
| MethyPatch |
| Metilfenidat hydrochloride |
| Metilfenidato |
| Metilfenidato [INN-Spanish] |
| Metilfenidato [Italian] |
| MLS003922100 |
| NCGC00091942-01 |
| NCGC00248587-01 |
| NCGC00257863-01 |
| NCI-C56280 |
| NSC 169868 |
| NSC-169868 |
| NSC-759278 |
| NSC169868 |
| NSC759278 |
| Pharmakon1600-01505907 |
| Phenidylate |
| phenyl-piperidin-2-yl-acetic acid methyl ester |
| Plimasine |
| PMS-Methylphenidate |
| QuilliChew ER |
| Quillivant XR |
| Quillivant xr (TN) |
| Rilaline |
| Rilatine |
| Riphenidate |
| Ritalin |
| Ritalin (Salt/Mix) |
| Ritalin (TN) |
| Ritalin hy drochloride |
| Ritalin hydrochloride |
| Ritalin SR |
| Ritalin-SR |
| Ritaline |
| Ritaline (Salt/Mix) |
| Ritcher works |
| Rubifen |
| SBI-0206868.P001 |
| SC-83308 |
| SCHEMBL37178 |
| SCHEMBL41067 |
| SMR000058998 |
| threo-Methyl |A-phenyl-|A-(2-piperidyl)acetate hydrochloride |
| Tox21_111186 |
| Tox21_200309 |
| TRANSGENIC MODEL EVALUATION (METHYLPHENIDATE HYDROCHLORIDE) (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE) |
| Tsentedrin |
| WLN: T6MTJ BYR & VO1 & GH |
Paragraph IV (Patent) Challenges for RITALIN LA
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| RITALIN LA | CAPSULE, EXTENDED RELEASE;ORAL | methylphenidate hydrochloride | 021284 | 2007-05-21 |
| RITALIN LA | CAPSULE, EXTENDED RELEASE;ORAL | methylphenidate hydrochloride | 021284 | 2006-08-21 |
US Patents and Regulatory Information for RITALIN LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | AB1 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | AB1 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | AB1 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | AB1 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-005 | Oct 27, 2014 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RITALIN LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | Start Trial | Start Trial |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | Start Trial | Start Trial |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | Start Trial | Start Trial |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | Start Trial | Start Trial |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | Start Trial | Start Trial |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RITALIN LA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 348633 | Start Trial |
| New Zealand | 511442 | Start Trial |
| Australia | 2006343445 | Start Trial |
| China | 101259106 | Start Trial |
| Israel | 142896 | Start Trial |
| China | 101879140 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
